Author

M. Trajkovic-Arsic

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:metabolomics· 2 Organism:mouse· 2 Research Focus:host-pathogen & immune response· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

J. T. Siveke· 3 shared A. M. Winkelkotte· 1 shared A. Ridley· 1 shared A. Scarpa· 1 shared A. Schramm· 1 shared A. Tannapfel· 1 shared A. Walch· 1 shared B. Horsthemke· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. T. Siveke

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Development of a LRRC15-Targeted Radio-Immunotheranostic Approach to Deplete Pro-tumorigenic Mechanisms and Immunotherapy Resistance

C. M. Storey, M. Altai, K. M. Lueckerath, W. Zedan, H. Zhu, M. Trajkovic-Arsic, J. E. Park, N. Peekhaus, J. Siveke, H. Lilljebjorn, D. Abou, H. L. Marks, E. Ulmert, H. Lilja, A. Ridley, , D. Ulmert

This paper develops a radio-theranostic approach targeting LRRC15 to image and treat cancer, showing tumor reduction and reversal of immunotherapy resistance.

bioRxiv · Jan 30, 2024 · PreprintPharmacology & Toxicology

Epigenetic plasticity via adaptive DNA hypermethylation and clonal expansion underlie resistance to oncogenic pathway inhibition in pancreatic cancer

L. K. Godfrey, J. Forster, S.-T. Liffers, C. Schroeder, J. Koester, L. Henschel, K. U. Ludwig, M. Trajkovic-Arsic, D. Behrens, A. Scarpa, R. T. Lawlor, K. E. Witzke, B. Sitek, S. A. Johnsen, S. Rahmann, , J. T. Siveke

This study identifies adaptive DNA methylation changes and clonal expansion as mechanisms of resistance to MEKi in PDAC, showing reversibility upon drug withdrawal.

bioRxiv · May 20, 2022 · PreprintCancer Biology

Functional metabolic phenotyping of human pancreatic ductal adenocarcinoma

I. Heid, S. Karakaya, C. Muench, S. S. Lueong, A. M. Winkelkotte, S. T. Liffers, L. Godfrey, P. F. Cheung, K. Savvatakis, G. J. Topping, F. Englert, L. Kritzner, M. Grashei, T. Kunzke, N. Sun, , J. T. Siveke

This study identifies functional metabolic differences between PDAC subtypes and shows that non-invasive HP-MRS can detect glycolytic tumor metabolism.

bioRxiv · Jul 23, 2021 · PreprintCancer Biology

MYCN-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma

B. Tjaden, K. Baum, V. Marquardt, M. Simon, M. Trajkovic-Arsic, T. Kouril, B. Siebers, J. Lisec, J. T. Siveke, J. H. Schulte, U. Benary, M. Remke, J. Wolf, A. Schramm

This study shows that MYCN overexpression in neuroblastoma cells rewires metabolism, creating vulnerabilities that can be targeted with metabolic inhibitors.

bioRxiv · Sep 25, 2018Cancer Biology